Boehringer Ingelheim: CHMP recommends conditional marketing

CHMP positive opinion is based on evidence from the EFFISAYIL 1 trial, the largest clinical trial in patients with generalized pustular psoriasis (GPP) flares1 GPP is a rare and potentially

Related Keywords

Japan , Paris , France General , France , Petra Kienle , Carinne Brouillon , Global Consensus Delphi Panel , Corporate Communications , Boehringer Ingelheim , European Medicine Agency , Medicinal Products , Human Use , Saint Louis University Hospital , Managing Directors , Human Pharma , Boehringer , Ingelheim , Thmp , Ecommends , Onditional , Marketing , Authorization , Spesolimab , First , Glass , Treatment , Option , Generalized , Pustular , Psoriasis , Uglares ,